

						an OPKO Hearth Company
PATIENT INF	ORMATION			ACCOUNT IN	IFORMATIO	N
First Name	_ast Name		GeneDx Account Numbe	r	Account Name	•
	Date of Birth (mm/dd/yy)		Phone		Fax	
Gender Identification (optional): Ancestry	○ Plook/A	African American	Address		City	
O Native American O East Asian	n O South A		State	Zip Code	Country	
○ Middle Eastern ○ Ashkenaz Email	i Jewish O Other: _		Ordering Provider Name			Role/Title
Address			NPI		Phone Number	
City	State	Zip Code	NEI			
Driver Dhane		·	Send Report Via	○ Fax ○ Email Fax #/Email:	O Portal	
-	s this patient deceased? Deceased Date:	○ Yes ○ No	Additional Reporting Pro	ovider's Name		
SAMPLE INF	ORMATION		Send Report Via	○ Fax ○ Email Fax #/Email:	O Portal	
	Medical Record #		SEND ADDITIONAL REPO			
	.,		Provider Name		GeneDx Acct#	
O Blood O Buccal Swab O Other (specification has had a blood transfusion Yes	ecify source): O No Date of Las	st Transfusion:	Fax #/Email:		l.	
(2-4 weeks of wait time is required for some testing)		Translation			1	
Patient has had an allogenic bone marrow transplant Fibroblasts are recommended for patients who had an		ansplant.		ICD-10 COD	ES (Require	d)
See www.genedx.com/specimen-requirements for deta		·	ICD-10 Codes			
○ Treatment-Related RUSH	Date:		Clinical Diagnosis			Age of Onset
PATIENT CONSENT FOR GENETIC TESTING, F	INANCIAL AGREEMEI	NT AND GUARANTEE:				
single comprehensive report that will be made availab providers. By my signature below, I accept full and cor testing ordered by my healthcare provider. For insuran bill my health insurance plan on my behalf, to release designated representative for purposes of appealing a direct that payment be made to GeneDx. I understand than the estimated amount indicated to me by GeneDb be financially responsible for any and all amounts as in	mplete financial responsib ice billing, I understand an any information required t iny denial of benefits. I irre I that my out-of-pocket co x as part of a benefit inves	illity for all genetic ad authorize GeneDx to for billing, and to be my evocably assign to and lists may be different stigation and agree to	a disease, illness, impair patient's medical manag (v) have obtained this pa	ment, symptom, syndrome ement and treatment decisi tient's and relatives', when d; and (vi) that the full and a y.	or disorder; (iv) the ons of this patier applicable, writte	the diagnosis and/or treatment of he test results will determine my nt's condition on this date of service informed consent to undergo any losis code(s) are indicated to the
my health insurance plan. I am aware that my insuran services performed by GeneDx on my behalf. I agree to						
GeneDx within 30 days of receipt as payment towards I agree to pay for the full cost of the genetic testing the				PAYMENT OPTION	ONS (Select	One)
billed to me by GeneDx. I further understand and agre- in accordance with the payment policies of GeneDx, m collection agency for non-payment and I agree to pay fees.	ny account may be turned	over to an external	O INSURANCE BILL (select all that applies)	Patient Status O Hospital outpatient O Not a hospital patient	· · ·	patient; Date of Discharge
More information, including the GeneDx Notice of Priva	acy Policies, is available o	n GeneDx's website:	Commercial Medicaid	Name of Insurance Carrier	•	Insurance ID#:
www.genedx.com	PM\ in required for Medice	ro potionto Plagos vigit	Medicare Tricare	Relationship to Insured Self		Policy Holder's Name
Medicare: A completed Advance Beneficiary Notice (Afour website, www.genedx.com/billing for more inform		re patients. Please visit	FOR ALL INSURANCE CARDS PROVIDE FRONT	O Spouse O Child O Other:		Policy Holder's Date of Birth
O By checking this box, I confirm that I am a New Yor to retain any remaining sample longer than 60 day de-identified sample for test development and imp and training purposes. Otherwise, New York law re	s after the completion of to provement, internal validat	testing to be used as a tion, quality assurance,	AND BACK COPY OF CARD(S)	Referral/Prior Authorizatio attach) Secondary Insurance Type		GeneDx Benefit Investigation #
and it cannot be used for the studies listed above.				Insurance Carrier Insu	urance ID #	Subscriber Name Date of Birth
Check this box if you wish to opt out of being cont	acted for research studies). 		Relationship to Insured:	O Child	Othor.
			O PATIENT BILL Amount Due:	for this testing. I agree that insurance for this testing,	am electing to be t neither GeneDx	Other: e treated as a self-pay patient k nor I will submit a claim to my ce. GeneDx will send an invoice to
Signature of Patient/Guardian (required)		Date		the patient listed above. Authorized Patient/Guardia	an Signature	
Signature of Relative A		Date	O INSTITUTIONAL BILL	GeneDx Account #		
Signature of Relative B		Date		Hospital/Lab Name		Place Sticker/Stamp Here

CLINICAL INFORMATION

t Name	Last Name	Date of Birth
CLINICAL	INFORMATION (DETAILED MEDICAL RECORDS MUST BE	ATTACHED)
urrent Diagnosis:		Age of Onset:
O Unilateral O Bilateral Disease	Consanguinity: O Yes	No
traocular Pressure:	ERG Results:	
udiogram (dB): Left Right		
Eye/Vision Abnormalities	Developmental/Behavi	oral
Abnormality of Vision	O Absent speech	
O Aniridia	 Delayed fine motor deve 	elopment
Anophthalmia	 Delayed gross motor de 	
Astigmatism	O Delayed speech & langu	
O Blue sclerae	Failure to thrive	
O Cataracts	 Incoordination 	
O Coloboma	Intellectual disability	
O Corneal arcus		
O Ectopia lentis	Renal	
O Esotropia	 Renal cysts 	
External ophthalmoplegia	Other renal:	<u></u>
O Hyperopia	Hearing Impairment	
O Hypoplasia of the fovea	O Abnormal newborn scre	een:
Keratoconus/Anterior Lenticonus	 Aminoglycoside-induced 	
Microphthalmia	 Conductive hearing imp 	
	○ bilateral ○ unilater	
O Myopia	O Enlarged Vestibular Aqu	
Ontio Atronhy	O Hearing impairment, mi	
Optic Atrophy	O bilateral O unilater	
O Photophobia	O Morphological Abnorma	
O Ptosis	 Sensorineural hearing in 	-
O Retinal detachment	O bilateral O unilater	
O Retinitis pigmentosa	O Tinnitus	ai
O Strabismus		
O Visual impairment	Hematologic or Immun O Recurrent infections	nologic Issues
Craniofacial/Dysmorphism	Recurrent otitis media	
O Abnormal facial shape (Dysmorphic features)		
O External ear malformation	Neurological Findings	
O Macrocephaly	Vocal cord paresis	
Microcephaly	Skin/Hair Findings	
	 Allergic dermatitis 	
	 Anhidrosis/Hypohidrosis 	
	Cutaneous photosensitive	
	O Dermatitis	•
	O Hypopigmentation of the	e skin
	O Ichthyosis	
	Skin fragility/blistering	
Include additional clinical information:	O Sparse hair	
moidue additional chinical lillothiduoti.	O Oparoo nan	



GeneDx Account #	Account Name					
First Name	Last Name		Date of Birth			
	REASON FOR EXPE	DITED TESTING (REQUIRED)				
O Pregnancy (gestational ageweeks)	splantation	Other:				
		ESTING AND SPECIAL SERVICES				
Individual to be tested: O Affected/Symptomatic	Unaffected/Asympton					
O Known Familial Variant(s) in a Nuclear Gene		d Mosaic Variant Testing nce Billing NOT Accepted; Patient Bill or Ins	c Variant Testing ing NOT Accepted; Patient Bill or Institutional Bill MUST be selected on page 1)			
Known Familial Copy Number variant(s)	○ Known	mtDNA Variant(s) Testing				
O Confirmation of Variant Identified in Research Lab						
Proband Name: Rela	tionship to Proband:	Proband Gene	eDx Accession #:			
Non-GeneDx Test: O Family member test report included (reco	mmended if previous test v	vas performed at another lab)				
		ended if previous test was performed at an	other lab.			
O Positive control not available (caveat lang Variant Information (please fill out the below information if fami	_					
Number of Variants:	ly monibor report to not in	nuuou				
Gene: Coding DNA (c	c.):	Amino Acid (p.):	Transcript (NM#):			
	c.):					
Copy Number Variants (CNV(s) require coordinates and genome	build or transcript # and e	xon #)				
Number of Variants:						
Gene(s): Exon #:		Coordinates:	Genome Build: _			
Gene(s): Exon #:		Coordinates: Genome Build:				
CUSTOM DEL/DUP TESTING						
O 906 Deletion/Duplication Analysis of ONE nuclear ge	ne 0 703	Deletion/Duplication Analysis of 2-20	nuclear genes			
Write in desired gene(s) to be tested:	<u>'</u>					
WRITE-IN TEST SELECTION						
○ Test Code: Test Name:						
		HISTORY				
FAMILY HISTORY						
O No Known Fam	ily History	O Pedigree Attached	Adopted			
RELATIONSHIP TO INDIVIDUAL TO BE TESTED MATERNAL PATERNA	L RELEVANT HISTORY			AGE AT DX		
0 0						
0						
0 0						
TESTING HISTORY						
O Test report included (recommended)						
Other relevant results (clinical, laboratory/biochemical or research):						



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

HEARING LOSS TESTS						
TEST CODE	# GENES	GENE LIST				
O J806	149	ABHD12, ACTB, ACTG1, ADCY1, AIFM1, ALMS1, ANKH, ATP6V1B1, BDP1, BSND, CABP2, CACNA1D, CCDC50, CD164, CDC14A, CDH23, CEACAM16, CHD7, CIB2, CLDN14, CLIC5, CLPP, CLRN1, COCH, COL2A1, COL11A1, COL11A2, COL4A3, COL4A4, COL4A5, COL4A6, CRYM, DCDC2, DFNA5, DIABLO, DIAPH1, DIAPH3, DNMT1, DSPP, EDN3, EDNRB, ELMOD3, EPS8, ESPN, ESRRB, EYA1, EYA4, FAM65B, FGF3, FGFR1, FGFR2, FGFR3, FOX11, GATS3, GIPC3, GLA1, GLB2, GLB3, GLB6, GRP98, GPSM2, GRHL2, GRXCR1, HARS2, HGF, HOMER2, HSD17B4, ILDR1, KARS, KCNE1, KCNJ10, KCNQ1, KCNQ4, KITLG, LARS2, LHFPL5, LRTOMT, MARVELD2, MCM2, MIR96, MITFMSRB3, MT-RNR1^, MT-TL1^, MT-TS1^, MYH14, MYH9, MY015A, MY03A, MY06, MY07A/NDP, NLRP3, OPA1, OSBPL2, OTOA, OTOF, OTOG, OTOGL, P2RX2, PAX3, PCDH15, PDZD7, DFNB59, PMP22, PNPT1, POUJF3, POLHF1, PDL974, PDL974				
O TA49	2	GJB2/GJB6 common deletions				
O 130	1	GJB2 (Cx26)^				
O 157	1	GJB6 (Cx30)^				
O 572	1	SLC26A4^				

	OPHTHALMOLOGY XPANDED PANELS							
TEST CODE	TEST NAME		# GENES	TEST CODE	CODE TEST NAME			# GENES
○ J894	Nystagmus Xpanded (Proband only or Trio)		~825	O J905	Retir	Retinal Dystrophy Xpanded (Proband only or Trio)		~875
BIOLOGICAL	PARENT SAMPLE IN	IFORMATION						
'ADDITIONAL S	SAMPLES MUST BE RE	CEIVED WITHIN 3 WEEKS.						
Mother:		O Not available	O To be sent within 3 weeks*		(O At GeneDx		
First Name		Last Name	DOB		(Asymptomatic	Symptomatic	
Father:		O Not available	O To be sent v	within 3 weeks*	O At GeneDx			
First Name		Last Name	DOB	Asymptomatic Symptomatic				
Other: Relationship:		O Not available	O To be sent v	vithin 3 weeks*	(O At GeneDx		
First Name		Last Name	DOB		(Asymptomatic	 Symptomatic 	

	OPHTHALMOLOGY MULTI-GENE PANELS					
TEST CODE	TEST NAME	# GENES	GENE LIST			
O J957	Anophthalmia and Microphthalmia Panel	23	ALDH1A3, BCOR, BMP4, BMP7, COX7B, CRYBA4, FOXE3, GDF6, HCCS, MITF, NAA10, NDUFB11, OTX2, PAX6, PRSS56, RAX, SALL1, SHH, SIX6, SOX2, STRA6, TENM3, VSX2 (CHX10)			
O J958	Cataracts Panel	86	ABCA3, ADAMTSL4, AGK, AKR1E2, ALDH18A1, BCOR, BEST1, BFSP1, BFSP2, CHMP4B, COL11A1, COL2A1, COL4A1, COL4A2, CRYAA, CRYAB, CRYBA1, CRYBA2, CRYBA4, CRYBB1, CRYBB2, CRYBB3, CRYGB, CRYGC, CRYGD, CRYGS, CTDP1, CYP2TA1, CYP51A1, EPG5, EPHA2, FAM126A, FOXC1, FOXE3, FTL, FYCO1, FZD4, GALK1, GCNT2, GFER, GJA1, GJA3, GJA8, HMX1, HSF4, JAM3, LIM2, LSS, LONP1, MAF, MIP, MIR184, MYH9, NDP, NF2, NHS, OCRL, OPA3, P3H2, PAX6, PITZ, PITX3, PXDN, RAB18, RAB3GAP1, RAB3GAP2, RECOL4, RGS6, RNLS, RRAGA, SC5D, SIL1, SIPA1L3, SIX6, SLC16A12, SLC33A1, TBC1D20, TDRD7, TFAP2A, TMEM70, UNC45B, VIM, VSX2, WDR87, WFS1, WRN			
O J956	Cone-Rod Dystrophy Panel	31	ABCA4, ADAM9, AIPL1, BEST1, C80RF37, CABP4, CACNA1F, CDH3, CDHR1, CEP290, CERKL, CNGA3, CNGB3, CRX, DRAM2, ELOVL4, GUCA1A, GUCY2D, PAX6, PITPNM3, POC1B, PROM1, PRPH2 (RDS), RAB28, RAX2 (QRX), RDH5, RIMS1, RPGR, RPGRIP1, SEMA4A, TTLL5			
O J959	Congenital Stationary Night Blindness Panel	12	CABP4, CACNA1F, CHM, GNAT1, GRM6, NYX, PDE6B, RDH5, RHO, RPE65, SAG, and TRPM1			
O J955	Familial Exudative Vitreoretinopathy (FEVR) Panel	4	FZD4, LRP5, NDP, TSPAN12			
O J960	Glaucoma Panel	37	ADAMTS10, ASB10 (GLC1F), BEST1, BMP4, COL4A1, COL8A2, CREBBP, CYP1B1, FBN1, FOXC1, FOXE3, GJA1, ISPD, LMX1B, LTBP2, MAF, MYOC, NTF4, OPA1, OPA3, OPTC, OPTN, PAX6, PIK3R1, PITX2, PITX3, POMT1, PRSS56, PXDN, RPS19, RRM2B, SBF2, SH3PXD2B, SIX6, TBK1, TMEM126A, TTR, WDR36.			
О ТВ48	Hermansky-Pudlak Syndrome Panel	10	AP3B1, AP3D1, BL0C1S3, BL0C1S6, DTNBP1, HPS1, HPS3, HPS4, HPS5, HPS6			
O 577	Progressive External Ophthalmoplegia (PEO)/ Optic Atrophy Nuclear Gene Panel	44	ACO2, AUH, C12orf65, CLPB, DGUOK, DNA2, DNAJC19, DNM1L, EARS2, FH, GYG2, ISCA2, MFF, MFN2, MGME1, MTFNT, MTO1, MTPAP, NARS2, NDUFAF3, NR2F1, OPA1, OPA3, PDHX, PDSS1, POLG, POLG2, RNASEH1, RRM2B, SLC19A2, SLC19A3, SLC25A4, SLC25A46, SPG7, SUCLA2, TACO1, TIMM8A, TK2, TMEM126A, TSFM, TWNK, TYMP, VARS2, WFS1			
O 466	Stargardt Disease Panel	3	ABCA4, ELOVL4 and PRPH2 (RDS)			
O TA02	Stickler Syndrome Panel	6	COL2A1, COL9A1, COL9A2, COL9A3, COL11A1, COL11A2			
О тооб	Usher Syndrome Panel	10	ADGRV1 (GPR98), CDH23, CLRN1, DFNB31 (WHRN), MY07A, PCDH15, USH1C, USH1G, USH2A and PDZD7			
O TH12	Leber Hereditary Optic Neuropathy (LHON) Panel					

All sequencing tests include del/dup analysis unless indicated by a $\ ^{\wedge}$ or otherwise noted.



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

	OPHTHALMOLOGY SINGLE GENE TESTS						
TEST CODE	TEST NAME/GENE NAME	DISORDER LIST	TEST CODE	TEST NAME/GENE NAME	DISORDER LIST		
○ TA84	AIPL1	Autosomal Dominant Cone-Rod Dystrophy Autosomal Recessive Leber Congenital Amaurosis	○ TB08	GNAT1	Axenfeld-Rieger Syndrome Peter's Anomaly		
3693	BCOR	Oculofaciocardiodental Syndrome	○ TA95	GUCA1A	Rieger Syndrome Autosomal Dominant Cone-Rod Dystrophy		
O 370	BCOR P85L Variant	Microphthalmia Lenz Syndrome	17100	3557.77	Autosomal Dominant Retinitis Pigmentosa		
	BEST1	Best Vitelliform Macular Dystrophy	O TA82	GUCY2D	Autosomal Recessive Leber Congenital Amaurosis		
		Autosomal Recessive Bestrophinopathy	O 189	HPS3	Hermansky-Pudlak Syndrome: Ashkenazi Splice Mutation		
		Adult-onset Foveomacular Vitelliform Dystrophy	O 188	HPS1^, HPS3	Hermansky-Pudlak Syndrome: Puerto Rican Mutations		
		Autosomal Dominant Retinitis Pigmentosa Autosomal Dominant Vitreoretinochoroidopathy	○ TA88	IMPDH1	Autosomal Dominant Cone-Rod Dystrophy Autosomal Dominant Retinitis Pigmentosa		
○ TB09	CABP4	Autosomal Recessive Congenital Stationary Night Blindness	○ TB25	LCA Tier 6 RPGRIP1	Autosomal Recessive Leber Congenital Amaurosis		
○ TB06	CACNA1F	X-Linked Congenital Stationary Night Blindness	○ TB05	NR2E3	Enhanced S-Cone Syndrome; Goldmann-Favre Syndrome Autosomal Dominant Retinitis Pigmentosa		
○ TA98	CERKL	Autosomal Recessive Cone-Rod Dystrophy Autosomal Recessive Retinitis Pigmentosa	○ TA92	NYX	Autosomal Recessive Retinitis Pigmentosa		
O 376	CEP290^	Autosomal Recessive Leber Congenital Amaurosis	○ TB17	PITX2	Axenfeld-Rieger Syndrome Peter's Anomaly		
	СНМ	Choroideremia	0		Rieger Syndrome		
○ TA90	CNGA1	Autosomal Recessive Retinitis Pigmentosa	○ TB24	PRPF3	Autosomal Dominant Retinitis Pigmentosa		
○ TB01	CNGA3	Achromatopsia; Autosomal Recessive Cone-Rod Dystrophy	_ C TA68	PRPH2 (RDS)	Autosomal Dominant Cone-Rod Dystrophy Autosomal Dominant Macular Degeneration Autosomal Dominant Retinitis Pigmentosa		
○ TA99	CNGB3	Achromatopsia; Autosomal Recessive Cone-Rod Dystrophy	○ TB50	RB1	Hereditary Retinoblastoma		
○ TA83	CRB1	Autosomal Recessive Leber Congenital Amaurosis	○ TA91	RDH5	Autosomal Recessive Retinitis Pigmentosa		
○ TA76	CRX	Autosomal Dominant Cone-Rod Dystrophy Autosomal Dominant Macular Degeneration	○ TA67	RHO	Congenital Stationary Night Blindness Autosomal Dominant Retinitis Pigmentosa		
○ TB18	FOXC1	Autosomal Dominant Retinitis Pigmentosa Axenfeld-Rieger Syndrome	○ TB28	RLBP1	Bothnia Retinal Dystrophy; Fundus Albipunctatus Newfoundland Rod-Cone Dystrophy Retinitis Punctata Albescens		
		Peter's Anomaly Rieger Syndrome		RPE65	Autosomal Recessive Leber Congenital Amaurosis		
		Iris Hypoplasia	○ TA72	RP2	X-Linked Retinitis Pigmentosa		
O 604	FOXE3^	Anterior Segment Dysgenesis Developmental Eye Disorders	O 2571	RS1^	Juvenile X-Linked Retinoschisis		
O T400	FDMDZ	V Limited Connectical Mustacons	○ TB02	SAG	Autosomal Recessive Congenital Stationary Night Blindness		
	FRMD7	X-Linked Congenital Nystagmus	○ TA96	TRPM1	Autosomal Recessive Congenital Stationary Night Blindness		

All sequencing tests include del/dup analysis unless indicated by a $^{\wedge}$ or otherwise noted.

INFORMED CONSENT



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

General Information About Genetic Testing

What is genetic testing?

DNA provides instructions for our body's growth and development. Genes are distinct sequences of DNA, and are arranged on chromosomes. The DNA in a gene contains instructions for making proteins, which determine things like growth and metabolism as well as traits like eye color and blood type. Genetic disorders are caused by certain changes in DNA affecting the structure or number of chromosomes. Genetic testing is a laboratory test that tries to identify these changes in chromosomes or the DNA. Genetic testing can be a diagnostic test, which is used to identify or rule out a specific genetic condition. Genetic screening tests are used to assess the chance for a person to develop or have a child with a genetic condition. Genetic screening tests are not typically diagnostic and results may require additional testing.

The purpose of this test is to see if I, or my child, may have a genetic variant or chromosome rearrangement causing a genetic disorder or to determine the chance that I, or my child, will develop or pass on a genetic disorder in the future. 'My child' can also mean my unborn child, for the purposes of this consent.

If I/my child already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I will inform the laboratory of this information.

What could I learn from this genetic test?

The following describes the possible results from the test:

- 1) Positive: A positive result indicates that a genetic variant has been identified that explains the cause of my/my child's genetic disorder or indicates that I/my child am at increased risk to develop the disorder in the future. It is possible to test positive for more than one genetic variant.
- 2) Negative: A negative result indicates that no disease-causing genetic variant was identified by the test performed. It does not guarantee that I/my child will be healthy or free from genetic disorders or medical conditions. If I/my child test negative for a variant known to cause the genetic disorder in other members of my/my child's family, this result rules out a diagnosis of the same genetic disorder in me/my child due to this specific change.
- 3) Inconclusive/Variant of Uncertain Significance (VUS): A finding of a variant of uncertain significance indicates that a genetic change was detected, but it is currently unknown whether that change is associated with a genetic disorder either now or in the future. A variant of uncertain significance is not the same as a positive result and does not clarify whether I/my child is at increased risk to develop a genetic disorder. The change could be a normal genetic variant or it could be disease-causing. Further analysis may be recommended, including testing parents and other family members. Detailed medical records or information from other family members also may be needed to help clarify results.
- 4) Unexpected results: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may tell me about the risk for another genetic condition I/my child is not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. This information may be disclosed to the ordering health care provider if it likely impacts medical care.

Result interpretation is based on currently available information in the medical literature, research and scientific databases. Because the literature, medical and scientific knowledge are constantly changing, new information that becomes available in the future may replace or add to the information GeneDx used to interpret my/my child's results. Providers can contact GeneDx at any time to discuss the classification of an identified variant. In addition, I or my/my child's health care providers may monitor publicly available resources used by the medical community, such as ClinVar (www.clinvar.com), to find current information about the clinical interpretation of my/my

For tests that evaluate data from multiple family members, my spouse, or partner concurrently, results may be included in a single comprehensive report.

What is Trio/Duo-based genetic testing?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents. Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my/my child's test results. The patient report may include clinical and genetic information about a relative when it is relevant to the interpretation of the results. Relatives do not receive an independent analysis of data nor a separate report.

What are the risks and limitations of this genetic test?

- Genetic testing is an important part of the diagnostic process. However, genetic tests may not always give a definitive answer. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing
- · Accurate interpretation of test results may require knowing the true biological relationships in a family. Failing to accurately state the biological relationships in my/my child's family may result

in incorrect interpretation of results, incorrect diagnoses, and/or inconclusive test results. In some cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. This includes non-paternity (the stated father of an individual is not the biological father) and consanguinity (the parents of an individual are related by blood). It may be necessary to report these findings to the health care provider who ordered the test.

- Genetic testing is highly accurate. Rarely, inaccurate results may occur for various reasons. These reasons include, but are not limited to: mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or unusual circumstances such as bone marrow transplantation, or the presence of change(s) in such a small percentage of cells that the change(s) may not be detectable by the test (mosaicism).
- This test does not have the ability to detect all of the long-term medical risks that I/my child might experience. The result of this test does not guarantee my health or the health of my child/ fetus. Other diagnostic tests may still need to be done, especially when only a genetic screening test has been performed previously.
- · Occasionally, an additional sample may be needed if the initial specimen is not adequate.

Patient Confidentiality and Genetic Counseling

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area here: www.nsgc.org. Further testing or additional consultations with a health care provider may be necessary.

To maintain confidentiality, the test results will only be released to the referring health care provider, to the ordering laboratory, to me, to other health care providers involved in my/my child's diagnosis and treatment, or to others as entitled by law. The United States Federal Government has enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, I understand that I can visit www.genome.gov/10002077.

International Specimens

If I/my child reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my/my child's

Additional information about the specific test being ordered is available from my health care provider or I can go to the GeneDx website, www.genedx.com.This information includes the complete gene lists, the specific types of genetic disorders that can be identified by the genetic test, the likelihood of a positive result, the limitations of genetic testing, as well as information about how specimens and information are stored and used.

Specimen Retention

After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring heath care providers unless specific prior arrangements

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and will not be retained for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. No tests other than those authorized shall be performed on the biological sample.

Database Participation

De-identified heath history and genetic information can help health care providers and scientists understand how genes affect human health. Though {I/my child} may not personally benefit, sharing this information helps health care providers to provide better care for their patients and researchers to make discoveries. GeneDx shares this type of information with health care providers, scientists and health care databases. No personal identifying information will be shared, as it will be replaced with a unique code.

Even though only a code is used for the reporting to the database, there is a risk that {I/my child} could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared {my/my child's} genetic or health information with public resources, such as genealogy websites.

Recontact for Research Participation

Separate from the above, GeneDx may collaborate with scientists, researchers and drug developers to advance knowledge of genetic diseases and to develop new treatments. If there are opportunities to participate in research relevant to the disorder in {my/my child's} family, and if I have consented for recontact, GeneDx may allow my healthcare provider to be recontacted for research purposes, such as the development of new testing, drug development, or other treatment modalities. In some situations, such as if my health care provider is not available, I may be contacted directly.

Any research that results in medical advances, including new products, tests or discoveries, may have potential commercial value and may be developed and owned by GeneDx or the collaborating researchers. If any individuals or corporations benefit financially from these studies, no compensation will be provided to {my/my child} or {my/my child's} heirs.